See “Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation” on page 114-123.

**Supplementary Table 1.** Rates (per 100 PY) and Risks of Any First Adverse Events during the First Year of Treatment in Patients in ADA and VDZ

| Variable                                         | No. of events ADA/VDZ | Rates per 100 PY with CIs in ADA | Rates per 100 PY with CIs in VDZ |
|-------------------------------------------------|-----------------------|----------------------------------|----------------------------------|
| All                                             | 34/57                 | 45.7 (32.7–64.0)                 | 54.2 (41.8–70.3)                 |
| **Disease**                                     |                       |                                  |                                  |
| Ulcerative colitis                              | 11/25                 | 58.7 (32.5–105.9)                | 57.9 (39.1–85.7)                 |
| Crohn’s disease                                 | 23/32                 | 41.4 (27.5–62.3)                 | 51.6 (36.5–72.9)                 |
| **Age (yr)**                                    |                       |                                  |                                  |
| ≤ 35                                            | 10/10                 | 52.8 (28.4–92.2)                 | 43.7 (23.5–81.3)                 |
| 36–54                                           | 18/27                 | 43.0 (27.1–68.3)                 | 54.8 (37.6–79.9)                 |
| ≥ 55                                            | 6/20                  | 44.1 (19.8–98.2)                 | 60.5 (39.0–93.7)                 |
| **Sex**                                         |                       |                                  |                                  |
| Male                                            | 19/30                 | 41.5 (26.4–65.0)                 | 42.1 (29.4–60.2)                 |
| Female                                          | 15/27                 | 52.6 (31.7–87.3)                 | 79.5 (54.1–115.9)                |
| **Previous biological therapy**                 |                       |                                  |                                  |
| None                                            | 15/4                  | 43.7 (26.3–72.4)                 | 23.3 (8.7–62.0)                  |
| 1 Biological therapy                            | 18/10                 | 48.5 (30.6–67.0)                 | 32.3 (17.4–60.1)                 |
| ≥ 2 Biological therapies                        | 1/43                  | 34.5 (4.8–245.2)                 | 75.3 (55.9–101.6)                |
| **Time from the last biological therapy**       |                       |                                  |                                  |
| No biologic therapies (naïve) or from more than 6 mo | 18/25         | 42.0 (26.5–66.8)                 | 50.9 (34.4–75.3)                 |
| ≤ 6 mo                                          | 16/32                 | 50.7 (31.0–82.7)                 | 57.1 (40.4–80.1)                 |
| **Indication to therapy**                       |                       |                                  |                                  |
| Active disease                                   | 30/52                 | 44.6 (31.2–63.8)                 | 54.5 (41.5–71.5)                 |
| Post-surgery                                     | -                     | -                                | -                                |
| Intolerant to previous biologic therapy          | 4/5                   | 64.9 (24.4–173.0)                | 105.8 (44.0–254.3)               |
| **Azathioprine during the year before the start of the treatment** | | | |
| No                                              | 29/51                 | 42.3 (29.4–60.9)                 | 56.3 (42.8–74.1)                 |
| Yes                                             | 5/6                   | 85.8 (35.7–206.1)                | 41.1 (18.4–91.4)                 |
| **Steroids during the year before the start of the treatment** | | | |
| No                                              | 26/43                 | 46.2 (31.4–67.9)                 | 49.3 (36.6–66.5)                 |
| Yes                                             | 8/14                  | 44.3 (22.1–88.5)                 | 77.6 (45.9–130.9)                |
| **Azathioprine ongoing**                        |                       |                                  |                                  |
| No                                              | 28/46                 | 46.5 (32.1–67.3)                 | 52.1 (39.0–69.6)                 |
| Yes                                             | 6/11                  | 42.5 (19.1–94.5)                 | 65.1 (36.0–117.6)                |
| **Steroids ongoing**                            |                       |                                  |                                  |
| No                                              | 27/33                 | 46.2 (31.7–67.4)                 | 50.4 (35.8–60.9)                 |
| Yes                                             | 7/24                  | 43.9 (20.9–92.1)                 | 60.5 (40.5–90.2)                 |

PY, person-years; ADA, adalimumab; VDZ, vedolizumab; CIs, confidence intervals.